Robert Mindreanu

Dr. Robert Mindreanu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RMRobert Mindreanu
Robert Mindreanu
Irina Camelia ChişIrina Camelia Chiş
Irina Camelia Chiş
ASAlexandra Cristina Sevastre-Berghian
Alexandra Cristina Sevastre-Berghian
CLCristian Cezar Login
Cristian Cezar Login
ASAdina Stan
Adina Stan
ȘSȘoimița Mihaela Suciu
Șoimița Mihaela Suciu
N-acetylcysteine (NAC) is a glutathione precursor with established antioxidant and anti-inflammatory properties that has been investigated as a neuroprotective agent across multiple neurological conditions. This systematic review systematically mapped the clinical evidence for NAC across seven neurological disorders. PubMed and Cochrane Library were searched for studies published between 1 January 1995 and 31 December 2025. Twenty-three studies were included: traumatic brain injury (TBI, n = 6), Alzheimer’s disease (AD, n = 5), Parkinson’s disease (PD, n = 5), multiple sclerosis (n = 4), amyotrophic lateral sclerosis (n = 2), and migraine (n = 1); no eligible epilepsy studies were identified. The strongest evidence emerged for acute mild TBI, where early NAC administration significantly improved symptom resolution, and for PD, where combined intravenous/oral NAC improved dopamine transporter binding. In AD, nutraceutical formulations including NAC and other active compounds showed trends toward cognitive stabilization. Most included studies had a high or serious risk of bias, and only eight of 23 assessed oxidative stress biomarkers. NAC demonstrated a favorable safety profile across all conditions. Despite fragmented and heterogeneous evidence, the encouraging signals identified warrant large-scale randomized controlled trials with a standardized biomarker assessment.

24 September 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RMRobert Mindreanu
Robert Mindreanu
BFBogdan Florea
Bogdan Florea
DSDenisa Stefanescu
Denisa Stefanescu
OMOrlanda Moldovan
Orlanda Moldovan
SMSorin Claudiu Man
Sorin Claudiu Man
Simona ClichiciSimona Clichici
Simona Clichici
Background: The relationship between routine inflammatory biomarkers and EEG severity in critically ill children, evaluated using visual (Synek) grading and spectral qEEG, remains unclear. The aim of our study was to examine the associations between procalcitonin (PCT), C-reactive protein (CRP) and EEG severity. Methods: Single-centre retrospective cohort of 97 critically ill children were analysed (PICU, Romania; November 2022–February 2026), each contributing one EEG with an inflammatory biomarker measured within ≤24 h. The primary analysis was the Spearman correlation of PCT and CRP with Synek grade, supported by comparisons of cortical electrocerebral silence with preserved cortical activity (Synek 1–4). The secondary analysis comprised five age-adjusted partial Spearman correlations between biomarkers and spectral qEEG metrics in the spectral cohort (n = 71), BH-corrected within family. Results: PCT and CRP were markedly higher in cortical silence than in preserved activity (Mann–Whitney p-value = 9.6 × 10−6 and 4.1 × 10−6; adjusted OR ≈ 2 per ln-unit). Both markers showed a positive rank association across Synek grades (PCT ρ = +0.49; CRP ρ = +0.41; both BH-adjusted p-value < 10−4), driven by the Synek-5 step: within grades 1–4 neither was graded (PCT ρ = +0.19; CRP ρ = +0.08; both p-value > 0.1). None of the five secondary correlations suggested a moderate-to-strong association (ρ −0.14 to +0.08; all BH-adjusted p-value ≥ 0.668). Conclusions: PCT and CRP were elevated at the threshold of cortical electrocerebral silence but did not provide a graded severity index within Synek grades 1–4, nor did they associate with spectral qEEG, including in the full 10–20 subset. The spectral analysis was underpowered for weak effects and excluded the Synek-5 subset where the primary signal was localised.

2 October 2026 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
RMRobert Mindreanu
Robert Mindreanu
IMIrina Matei
Irina Matei
TSTeodora Stan
Teodora Stan
SCSimona Clichici
Simona Clichici
DMDafin MureșAnu
Dafin MureșAnu
ASAdina Stan
Adina Stan
Introduction: Myasthenic crisis is the most feared acute complication of myasthenia gravis (MG), yet simple clinic-based approaches to risk stratification remain limited. We examined which routinely recorded clinical features were associated with crisis occurrence across the observed disease course and whether a parsimonious model could provide retrospective group-level stratification. Methods: This single-centre retrospective study included 86 adults with MG. Myasthenic crisis was defined as respiratory failure requiring mechanical ventilation. Disease severity was graded using the Myasthenia Gravis Foundation of America (MGFA) classification and grouped as mild, moderate or severe; MGFA class V was excluded to avoid circularity. Independent correlates were assessed by logistic regression and internally validated by cross-validation. The model was intended for retrospective group-level stratification, not prospective prediction of an individual future crisis. Results: Thirty-four patients (40%) had experienced a myasthenic crisis. Crisis frequency increased across severity groups: 11%, 26% and 73% in mild, moderate and severe disease, respectively ( p < 0.001). Each severity grade increased the odds of crisis approximately seven-fold (OR 6.7, 95% CI 2.8–16.5), whereas more frequent outpatient visits were associated with lower odds (OR 0.73). The two-item model showed good discrimination (AUC 0.84; cross-validated AUC 0.79). Calibration-in-the-large was close to ideal, although the cross-validated calibration slope of 0.73 suggested moderate overfitting. Conclusions: MGFA severity was the dominant clinic-available marker of crisis occurrence. Outpatient-visit frequency contributed less stable information and should be considered exploratory. These findings support retrospective group-level stratification but do not establish prospective prediction or a protective effect of follow-up.

29 September 2026 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
RSRamona Simedrea
Ramona Simedrea
RMRobert Mindreanu
Robert Mindreanu
Simona ClichiciSimona Clichici
Simona Clichici
BBBianca Maria Buleteanu
Bianca Maria Buleteanu
MBMario Badea
Mario Badea
CLCristian Cezar Login
Cristian Cezar Login

Verified
Journal Article
Open access
PDF file
RMRobert Mindreanu
Robert Mindreanu
Simona ClichiciSimona Clichici
Simona Clichici
BBBianca Maria Buleteanu
Bianca Maria Buleteanu
MBMario Badea
Mario Badea
MPMihaela Pop
Mihaela Pop
CLCristian Cezar Login
Cristian Cezar Login
Oxidative stress is implicated in epilepsy, but seizures, disease severity, diet, comorbidity and treatment all influence circulating redox biomarkers. We systematically reviewed human evidence on levetiracetam (LEV) under three estimands: within-person change, LEV-treated epilepsy versus healthy controls, and LEV versus other antiseizure medications. PubMed/MEDLINE, Cochrane Library, Web of Science and Scopus were searched from inception to 15 July 2026 (PROSPERO CRD420261448016; OSF HXA4U). Eleven non-randomized studies contributed 297 participants—the sum of LEV subgroups with analysable biomarker data, not the total enrolled populations. Effect estimates with 95% confidence intervals were calculated here wherever reporting permitted; none could be derived for four studies, and those derived are wide, inconsistent in direction, or from designs that cannot attribute change to LEV. Meta-analysis was inappropriate: definitions, matrices, assays, estimands and variance reporting were incompatible. Certainty was very low for every outcome-domain/comparator body, and a sensitivity analysis excluding one report failing a post hoc source-verifiability check (10 studies, 265 participants) changed no conclusion. This review’s contribution is not an estimate of LEV’s redox effect but a demonstration of why the literature cannot establish one: the human evidence is not of sufficient validity to support or refute such an effect.